Literature DB >> 26280524

Development of novel antibodies against non-structural proteins nsP1, nsP3 and nsP4 of chikungunya virus: potential use in basic research.

Sameer Kumar1, Prabhudutta Mamidi1, Abhishek Kumar1, Itishree Basantray1, Umarani Bramha1, Anshuman Dixit1, Prasanta Kumar Maiti2, Sujay Singh2, Amol Ratnakar Suryawanshi1, Subhasis Chattopadhyay3, Soma Chattopadhyay4.   

Abstract

Chikungunya virus (CHIKV) has reemerged recently as an important pathogen, causing several large epidemics worldwide. This necessitates the development of better reagents to understand its biology and to establish effective and safe control measures. The present study describes the development and characterization of polyclonal antibodies (pAbs) against synthetic peptides of CHIKV non-structural proteins (nsPs; nsP1, nsP3 and nsP4). The reactivity of these pAbs was demonstrated by ELISA and Western blot. Additionally, in vitro infection studies in a mammalian system confirmed that these pAbs are highly sensitive and specific for CHIKV nsPs, as these proteins were detected very early during viral replication. Homology analysis of the selected epitope sequences revealed that they are conserved among all of the CHIKV strains of different genotypes, while comparison with other alphavirus sequences showed that none of them are 100% identical to the epitope sequences (except Onyong-nyong and Igbo Ora viruses, which show 100% identity to the nsP4 epitope). Interestingly, two different forms of CHIKV nsP1 and three different forms of nsP3 were detected in Western blot analysis during infection; however, further experimental investigations are required to confirm their identity. Also, the use of these antibodies demonstrated faster and enhanced expression profiles of all CHIKV nsPs in 2006 Indian outbreak strains when compared to the CHIKV prototype strain, suggesting the epidemic potential of the 2006 isolate. Accordingly, it can be suggested that the pAbs reported in this study can be used as sensitive and specific tools for experimental investigations of CHIKV replication and infection.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26280524     DOI: 10.1007/s00705-015-2564-2

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  13 in total

1.  Expression, purification and functional characterization of recombinant hypervariable region (HVR) of Chikungunya virus nsP3 protein.

Authors:  Ipsita Nandi; Amita Gupta; Vijay K Chaudhary; Vandana Gupta; Reema Gabrani; Sanjay Gupta
Journal:  3 Biotech       Date:  2019-05-27       Impact factor: 2.406

2.  Telmisartan Restricts Chikungunya Virus Infection In Vitro and In Vivo through the AT1/PPAR-γ/MAPKs Pathways.

Authors:  Prabhudutta Mamidi; Soumyajit Ghosh; Saikat De; Supriya Suman Keshry; Chandan Mahish; Sweta Smita Pani; Eshna Laha; Amrita Ray; Ankita Datey; Sanchari Chatterjee; Sharad Singh; Tathagata Mukherjee; Somlata Khamaru; Subhasis Chattopadhyay; Bharat Bhusan Subudhi; Soma Chattopadhyay
Journal:  Antimicrob Agents Chemother       Date:  2021-11-08       Impact factor: 5.938

3.  Inhibition of herpes simplex virus-1 infection by MBZM-N-IBT: in silico and in vitro studies.

Authors:  Abhishek Kumar; Saikat De; Alok Kumar Moharana; Tapas Kumar Nayak; Tanuja Saswat; Ankita Datey; Prabhudutta Mamidi; Priyadarsee Mishra; Bharat Bhusan Subudhi; Soma Chattopadhyay
Journal:  Virol J       Date:  2021-05-26       Impact factor: 4.099

4.  Broad-spectrum monoclonal antibodies against chikungunya virus structural proteins: Promising candidates for antibody-based rapid diagnostic test development.

Authors:  Aekkachai Tuekprakhon; Orapim Puiprom; Tadahiro Sasaki; Johan Michiels; Koen Bartholomeeusen; Emi E Nakayama; Michael K Meno; Juthamas Phadungsombat; Ralph Huits; Kevin K Ariën; Natthanej Luplertlop; Tatsuo Shioda; Pornsawan Leaungwutiwong
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

Review 5.  Potential Antivirals: Natural Products Targeting Replication Enzymes of Dengue and Chikungunya Viruses.

Authors:  Ana Flávia Costa da Silveira Oliveira; Róbson Ricardo Teixeira; André Silva de Oliveira; Ana Paula Martins de Souza; Milene Lopes da Silva; Sérgio Oliveira de Paula
Journal:  Molecules       Date:  2017-03-22       Impact factor: 4.411

6.  Western Blot Detection of Human Anti-Chikungunya Virus Antibody with Recombinant Envelope 2 Protein.

Authors:  Zhaoshou Yang; Jihoo Lee; Hye-Jin Ahn; Chom-Kyu Chong; Ronaldo F Dias; Ho-Woo Nam
Journal:  Korean J Parasitol       Date:  2016-04-30       Impact factor: 1.341

7.  Inhibition of Chikungunya Virus Replication by 1-[(2-Methylbenzimidazol-1-yl) Methyl]-2-Oxo-Indolin-3-ylidene] Amino] Thiourea(MBZM-N-IBT).

Authors:  Priyadarsee Mishra; Abhishek Kumar; Prabhudutta Mamidi; Sameer Kumar; Itishree Basantray; Tanuja Saswat; Indrani Das; Tapas Kumar Nayak; Subhasis Chattopadhyay; Bharat Bhusan Subudhi; Soma Chattopadhyay
Journal:  Sci Rep       Date:  2016-02-04       Impact factor: 4.379

8.  Chikungunya virus nsP1 interacts directly with nsP2 and modulates its ATPase activity.

Authors:  Sameer Kumar; Abhishek Kumar; Prabhudutta Mamidi; Atul Tiwari; Sriram Kumar; Animamalar Mayavannan; Sagarika Mudulli; Ajit Kumar Singh; Bharat Bhusan Subudhi; Soma Chattopadhyay
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

Review 9.  Chikungunya Virus: Pathophysiology, Mechanism, and Modeling.

Authors:  Vaishnavi K Ganesan; Bin Duan; St Patrick Reid
Journal:  Viruses       Date:  2017-12-01       Impact factor: 5.048

Review 10.  Current Strategies for Inhibition of Chikungunya Infection.

Authors:  Bharat Bhusan Subudhi; Soma Chattopadhyay; Priyadarsee Mishra; Abhishek Kumar
Journal:  Viruses       Date:  2018-05-03       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.